(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.03%) $0.926
(-0.09%) $10.83
(-0.14%) $0.791
(-0.24%) $92.35
Live Chart Being Loaded With Signals
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Today's Volume | 15.87M |
Average Volume | 16.86M |
Market Cap | 14.34B |
EPS | HKD0 ( 2024-03-20 ) |
Last Dividend | HKD0.100 ( 2023-06-27 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 8.93 |
ATR14 | HKD0.00800 (0.13%) |
Volume Correlation
3SBio Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
3SBio Inc Correlation - Currency/Commodity
3SBio Inc Financials
Annual | 2022 |
Revenue: | HKD6.86B |
Gross Profit: | HKD5.67B (82.69 %) |
EPS: | HKD0.780 |
Q2 | 2023 |
Revenue: | HKD1.89B |
Gross Profit: | HKD1.60B (84.61 %) |
EPS: | HKD0.200 |
Q1 | 2023 |
Revenue: | HKD1.89B |
Gross Profit: | HKD1.60B (84.61 %) |
EPS: | HKD0.200 |
Q4 | 2022 |
Revenue: | HKD1.88B |
Gross Profit: | HKD1.55B (82.45 %) |
EPS: | HKD0.190 |
Financial Reports:
No articles found.
3SBio Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0685 | 2018-06-29 |
Last Dividend | HKD0.100 | 2023-06-27 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.369 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.8 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.93 | |
Div. Directional Score | 8.57 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9919.HK | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
2182.HK | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
1199.HK | Ex Dividend Junior | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
0285.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
3888.HK | Ex Dividend Knight | 2023-06-02 | Annually | 0 | 0.00% | |
1772.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
0817.HK | Ex Dividend Junior | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
2342.HK | Ex Dividend Knight | 2023-09-07 | Annually | 0 | 0.00% | |
1336.HK | Ex Dividend Knight | 2023-07-06 | Annually | 0 | 0.00% | |
0392.HK | Ex Dividend Junior | 2023-09-22 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.257 | 1.500 | 4.86 | 7.29 | [0 - 0.5] |
returnOnAssetsTTM | 0.0838 | 1.200 | 7.21 | 8.65 | [0 - 0.3] |
returnOnEquityTTM | 0.147 | 1.500 | 9.48 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.215 | -1.000 | 7.85 | -7.85 | [0 - 1] |
currentRatioTTM | 2.88 | 0.800 | 0.601 | 0.481 | [1 - 3] |
quickRatioTTM | 2.25 | 0.800 | 1.469 | 1.175 | [0.8 - 2.5] |
cashRatioTTM | 0.582 | 1.500 | 7.88 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.215 | -1.500 | 6.42 | -9.64 | [0 - 0.6] |
interestCoverageTTM | 13.37 | 1.000 | 6.16 | 6.16 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.915 | 2.00 | 9.69 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.530 | 2.00 | 9.74 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.368 | -1.500 | 8.53 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.835 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.310 | 1.000 | 5.80 | 5.80 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.461 | 1.000 | 8.55 | 8.55 | [0.2 - 2] |
assetTurnoverTTM | 0.326 | 0.800 | -1.160 | -0.928 | [0.5 - 2] |
Total Score | 11.22 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 7.01 | 1.000 | 9.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.147 | 2.50 | 9.67 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.530 | 2.00 | 9.82 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.841 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.915 | 2.00 | 9.69 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.215 | 1.500 | 7.85 | -7.85 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.303 | 1.000 | 4.91 | 0 | [0.1 - 0.5] |
Total Score | 5.93 |
3SBio Inc
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators